Eton Pharmaceuticals, Inc.
ETON
$16.90
-$2.24-11.70%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 117.54% | 108.60% | 116.95% | 59.26% | 46.90% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 117.54% | 108.60% | 116.95% | 59.26% | 46.90% |
| Cost of Revenue | 230.18% | 68.13% | 150.79% | 40.40% | 53.22% |
| Gross Profit | 45.65% | 133.40% | 96.94% | 78.40% | 43.13% |
| SG&A Expenses | 53.29% | 73.26% | 77.85% | 37.74% | 21.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 129.22% | 59.85% | 102.51% | 13.94% | 29.55% |
| Operating Income | -107.66% | 90.87% | 41.25% | 152.38% | 192.88% |
| Income Before Tax | -490.22% | 15.67% | -84.71% | 74.56% | 186.53% |
| Income Tax Expenses | 77.78% | 22.22% | -- | -64.78% | -- |
| Earnings from Continuing Operations | -407.34% | 15.00% | -93.83% | 73.49% | 208.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -407.34% | 15.00% | -93.83% | 73.49% | 208.29% |
| EBIT | -107.66% | 90.87% | 41.25% | 152.38% | 192.88% |
| EBITDA | 23.25% | 127.75% | 195.94% | 176.60% | 320.45% |
| EPS Basic | -396.28% | 18.56% | -85.71% | 73.86% | 207.56% |
| Normalized Basic EPS | -221.49% | 57.87% | -76.65% | 95.29% | 185.82% |
| EPS Diluted | -458.50% | 16.67% | -85.71% | 68.26% | 188.89% |
| Normalized Diluted EPS | -224.58% | 57.87% | -76.65% | 95.29% | 183.69% |
| Average Basic Shares Outstanding | 3.83% | 4.33% | 4.36% | 1.53% | 0.70% |
| Average Diluted Shares Outstanding | 1.29% | 4.33% | 4.36% | 1.53% | 3.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |